1
|
Jordan C, Siebold K, Priegue P, Seeberger PH, Gilmour R. A Fluorinated Sialic Acid Vaccine Lead Against Meningitis B and C. J Am Chem Soc 2024. [PMID: 38768956 DOI: 10.1021/jacs.4c03179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/22/2024]
Abstract
Inspired by the specificity of α-(2,9)-sialyl epitopes in bacterial capsular polysaccharides (CPS), a doubly fluorinated disaccharide has been validated as a vaccine lead against Neisseria meningitidis serogroups C and/or B. Emulating the importance of fluorine in drug discovery, this molecular editing approach serves a multitude of purposes, which range from controlling α-selective chemical sialylation to mitigating competing elimination. Conjugation of the disialoside with two carrier proteins (CRM197 and PorA) enabled a semisynthetic vaccine to be generated; this was then investigated in six groups of six mice. The individual levels of antibodies formed were compared and classified as highly glycan-specific and protective. All glycoconjugates induced a stable and long-term IgG response and binding to the native CPS epitope was achieved. The generated antibodies were protective against MenC and/or MenB; this was validated in vitro by SBA and OPKA assays. By merging the fluorinated glycan epitope of MenC with an outer cell membrane protein of MenB, a bivalent vaccine against both serogroups was created. It is envisaged that validation of this synthetic, fluorinated disialoside bioisostere as a potent antigen will open new therapeutic avenues.
Collapse
Affiliation(s)
- Christina Jordan
- Institute for Organic Chemistry, University of Münster, Corrensstraße 36, Münster 48149, Germany
| | - Kathrin Siebold
- Institute for Organic Chemistry, University of Münster, Corrensstraße 36, Münster 48149, Germany
| | - Patricia Priegue
- Department of Biomolecular Systems, Max Planck Institute for Colloids and Interfaces, Am Mühlenberg 1, Potsdam 14476, Germany
- Freie Universität Berlin, Institute of Chemistry and Biochemistry, Arnimallee 22, Berlin 14195, Germany
| | - Peter H Seeberger
- Department of Biomolecular Systems, Max Planck Institute for Colloids and Interfaces, Am Mühlenberg 1, Potsdam 14476, Germany
- Freie Universität Berlin, Institute of Chemistry and Biochemistry, Arnimallee 22, Berlin 14195, Germany
| | - Ryan Gilmour
- Institute for Organic Chemistry, University of Münster, Corrensstraße 36, Münster 48149, Germany
| |
Collapse
|
2
|
Oldrini D, Di Benedetto R, Carducci M, De Simone D, Massai L, Alfini R, Galli B, Brunelli B, Przedpelski A, Barbieri JT, Rossi O, Giannelli C, Rappuoli R, Berti F, Micoli F. Testing a Recombinant Form of Tetanus Toxoid as a Carrier Protein for Glycoconjugate Vaccines. Vaccines (Basel) 2023; 11:1770. [PMID: 38140177 PMCID: PMC10747096 DOI: 10.3390/vaccines11121770] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2023] [Revised: 11/07/2023] [Accepted: 11/23/2023] [Indexed: 12/24/2023] Open
Abstract
Glycoconjugate vaccines play a major role in the prevention of infectious diseases worldwide, with significant impact on global health, enabling the polysaccharides to induce immunogenicity in infants and immunological memory. Tetanus toxoid (TT), a chemically detoxified bacterial toxin, is among the few carrier proteins used in licensed glycoconjugate vaccines. The recombinant full-length 8MTT was engineered in E. coli with eight individual amino acid mutations to inactivate three toxin functions. Previous studies in mice showed that 8MTT elicits a strong IgG response, confers protection, and can be used as a carrier protein. Here, we compared 8MTT to traditional carrier proteins TT and cross-reactive material 197 (CRM197), using different polysaccharides as models: Group A Streptococcus cell-wall carbohydrate (GAC), Salmonella Typhi Vi, and Neisseria meningitidis serogroups A, C, W, and Y. The persistency of the antibodies induced, the ability of the glycoconjugates to elicit booster response after re-injection at a later time point, the eventual carrier-induced epitopic suppression, and immune interference in multicomponent formulations were also evaluated. Overall, immunogenicity responses obtained with 8MTT glycoconjugates were compared to those obtained with corresponding TT and, in some cases, were higher than those induced by CRM197 glycoconjugates. Our results support the use of 8MTT as a good alternative carrier protein for glycoconjugate vaccines, with advantages in terms of manufacturability compared to TT.
Collapse
Affiliation(s)
- Davide Oldrini
- GSK Vaccines Institute for Global Health (GVGH), via Fiorentina 1, 53100 Siena, Italy; (D.O.); (R.D.B.); (M.C.); (D.D.S.); (L.M.); (R.A.); (O.R.); (C.G.)
| | - Roberta Di Benedetto
- GSK Vaccines Institute for Global Health (GVGH), via Fiorentina 1, 53100 Siena, Italy; (D.O.); (R.D.B.); (M.C.); (D.D.S.); (L.M.); (R.A.); (O.R.); (C.G.)
| | - Martina Carducci
- GSK Vaccines Institute for Global Health (GVGH), via Fiorentina 1, 53100 Siena, Italy; (D.O.); (R.D.B.); (M.C.); (D.D.S.); (L.M.); (R.A.); (O.R.); (C.G.)
| | - Daniele De Simone
- GSK Vaccines Institute for Global Health (GVGH), via Fiorentina 1, 53100 Siena, Italy; (D.O.); (R.D.B.); (M.C.); (D.D.S.); (L.M.); (R.A.); (O.R.); (C.G.)
| | - Luisa Massai
- GSK Vaccines Institute for Global Health (GVGH), via Fiorentina 1, 53100 Siena, Italy; (D.O.); (R.D.B.); (M.C.); (D.D.S.); (L.M.); (R.A.); (O.R.); (C.G.)
| | - Renzo Alfini
- GSK Vaccines Institute for Global Health (GVGH), via Fiorentina 1, 53100 Siena, Italy; (D.O.); (R.D.B.); (M.C.); (D.D.S.); (L.M.); (R.A.); (O.R.); (C.G.)
| | - Barbara Galli
- GSK, via Fiorentina 1, 53100 Siena, Italy; (B.G.); (B.B.); (F.B.)
| | | | - Amanda Przedpelski
- Department of Microbiology and Immunology, Medical College of Wisconsin, Milwaukee, WI 53226, USA; (A.P.); (J.T.B.)
| | - Joseph T. Barbieri
- Department of Microbiology and Immunology, Medical College of Wisconsin, Milwaukee, WI 53226, USA; (A.P.); (J.T.B.)
| | - Omar Rossi
- GSK Vaccines Institute for Global Health (GVGH), via Fiorentina 1, 53100 Siena, Italy; (D.O.); (R.D.B.); (M.C.); (D.D.S.); (L.M.); (R.A.); (O.R.); (C.G.)
| | - Carlo Giannelli
- GSK Vaccines Institute for Global Health (GVGH), via Fiorentina 1, 53100 Siena, Italy; (D.O.); (R.D.B.); (M.C.); (D.D.S.); (L.M.); (R.A.); (O.R.); (C.G.)
| | - Rino Rappuoli
- Fondazione Biotecnopolo, via Fiorentina 1, 53100 Siena, Italy;
| | - Francesco Berti
- GSK, via Fiorentina 1, 53100 Siena, Italy; (B.G.); (B.B.); (F.B.)
| | - Francesca Micoli
- GSK Vaccines Institute for Global Health (GVGH), via Fiorentina 1, 53100 Siena, Italy; (D.O.); (R.D.B.); (M.C.); (D.D.S.); (L.M.); (R.A.); (O.R.); (C.G.)
| |
Collapse
|
3
|
Khodak YA. Heterologous Expression of Recombinant Proteins and Their Derivatives Used as Carriers for Conjugate Vaccines. Biochemistry (Mosc) 2023; 88:1248-1266. [PMID: 37770392 DOI: 10.1134/s0006297923090055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/12/2023] [Revised: 06/30/2023] [Accepted: 07/25/2023] [Indexed: 09/30/2023]
Abstract
Carrier proteins that provide an effective and long-term immune response to weak antigens has become a real breakthrough in the disease prevention, making it available to a wider range of patients and making it possible to obtain reliable vaccines against a variety of pathogens. Currently, research is continuing both to identify new peptides, proteins, and their complexes potentially suitable for use as carriers, and to develop new methods for isolation, purification, and conjugation of already known and well-established proteins. The use of recombinant proteins has a number of advantages over isolation from natural sources, such as simpler cultivation of the host organism, the possibility of modifying genetic constructs, use of numerous promoter variants, signal sequences, and other regulatory elements. This review is devoted to the methods of obtaining both traditional and new recombinant proteins and their derivatives already being used or potentially suitable for use as carrier proteins in conjugate vaccines.
Collapse
Affiliation(s)
- Yuliya A Khodak
- Institute of Bioengineering, Federal Research Centre of Biotechnology, Russian Academy of Sciences, Moscow, 117312, Russia.
| |
Collapse
|
4
|
Kamneva AA, Yashunsky DV, Khatuntseva EA, Nifantiev NE. Synthesis of Pseudooligosaccharides Related to the Capsular Phosphoglycan of Haemophilus influenzae Type a. Molecules 2023; 28:5688. [PMID: 37570658 PMCID: PMC10419796 DOI: 10.3390/molecules28155688] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2023] [Revised: 07/21/2023] [Accepted: 07/25/2023] [Indexed: 08/13/2023] Open
Abstract
Synthesis of spacer-armed pseudodi-, pseudotetra-, and pseudohexasaccharides related to the capsular phosphoglycan of Haemophilus influenzae type a, the second most virulent serotype of H. influenzae (after type b), was performed for the first time via iterative chain elongation using H-phosphonate chemistry for the formation of inter-unit phosphodiester bridges. These compounds were prepared for the design of neoglycoconjugates, as exemplified by the transformation of the obtained pseudohexasaccharide derivative into a biotinylated glycoconjugate suitable for use in immunological studies, particularly in diagnostic screening systems as a coating antigen for streptavidin-coated plates and chip slides.
Collapse
Affiliation(s)
| | | | | | - Nikolay E. Nifantiev
- N. D. Zelinsky Institute of Organic Chemistry, Leninsky pr. 47, Moscow 119991, Russia; (A.A.K.); (D.V.Y.); (E.A.K.)
| |
Collapse
|
5
|
Akache B, Read AJ, Dudani R, Harrison BA, Williams D, Deschatelets L, Jia Y, Chandan V, Stark FC, Agbayani G, Makinen SR, Hemraz UD, Lam E, Régnier S, Zou W, Kirkland PD, McCluskie MJ. Sulfated Lactosyl Archaeol Archaeosome-Adjuvanted Vaccine Formulations Targeting Rabbit Hemorrhagic Disease Virus Are Immunogenic and Efficacious. Vaccines (Basel) 2023; 11:1043. [PMID: 37376432 DOI: 10.3390/vaccines11061043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2023] [Revised: 05/24/2023] [Accepted: 05/27/2023] [Indexed: 06/29/2023] Open
Abstract
Vaccines play an important role in maintaining human and animal health worldwide. There is continued demand for effective and safe adjuvants capable of enhancing antigen-specific responses to a target pathogen. Rabbit hemorrhagic disease virus (RHDV) is a highly contagious calicivirus that often induces high mortality rates in rabbits. Herein, we evaluated the activity of an experimental sulfated lactosyl archaeol (SLA) archaeosome adjuvant when incorporated in subunit vaccine formulations targeting RHDV. The subunit antigens consisted of RHDV-CRM197 peptide conjugates or recombinant RHDV2 VP60. SLA was able to enhance antigen-specific antibody titers and cellular responses in mice and rabbits. Three weeks following immunization, antigen-specific antibody levels in rabbits vaccinated with RHDV2 VP60 + SLA were significantly higher than those immunized with antigen alone, with geomean titers of 7393 vs. 117. In addition, the SLA-adjuvanted VP60-based formulations were highly efficacious in a rabbit RHDV2 challenge model with up to 87.5% animals surviving the viral challenge. These findings demonstrate the potential utility of SLA adjuvants in veterinary applications and highlight its activity in different types of mammalian species.
Collapse
Affiliation(s)
- Bassel Akache
- National Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada
| | - Andrew J Read
- Virology Laboratory, Elizabeth Macarthur Agricultural Institute, NSW Department of Primary Industries, Menangle, NSW 2567, Australia
| | - Renu Dudani
- National Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada
| | - Blair A Harrison
- National Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada
| | - Dean Williams
- National Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada
| | - Lise Deschatelets
- National Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada
| | - Yimei Jia
- National Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada
| | - Vandana Chandan
- National Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada
| | - Felicity C Stark
- National Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada
| | - Gerard Agbayani
- National Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada
| | - Shawn R Makinen
- National Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada
| | - Usha D Hemraz
- National Research Council Canada, Aquatic and Crop Resource Development, Montreal, QC H4P 2R2, Canada
| | - Edmond Lam
- National Research Council Canada, Aquatic and Crop Resource Development, Montreal, QC H4P 2R2, Canada
| | - Sophie Régnier
- National Research Council Canada, Aquatic and Crop Resource Development, Montreal, QC H4P 2R2, Canada
| | - Wei Zou
- National Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada
| | - Peter D Kirkland
- Virology Laboratory, Elizabeth Macarthur Agricultural Institute, NSW Department of Primary Industries, Menangle, NSW 2567, Australia
| | - Michael J McCluskie
- National Research Council Canada, Human Health Therapeutics, Ottawa, ON K1A 0R6, Canada
| |
Collapse
|
6
|
Efremenko E, Aslanli A, Lyagin I. Advanced Situation with Recombinant Toxins: Diversity, Production and Application Purposes. Int J Mol Sci 2023; 24:ijms24054630. [PMID: 36902061 PMCID: PMC10003545 DOI: 10.3390/ijms24054630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2022] [Revised: 02/14/2023] [Accepted: 02/20/2023] [Indexed: 03/04/2023] Open
Abstract
Today, the production and use of various samples of recombinant protein/polypeptide toxins is known and is actively developing. This review presents state-of-the-art in research and development of such toxins and their mechanisms of action and useful properties that have allowed them to be implemented into practice to treat various medical conditions (including oncology and chronic inflammation applications) and diseases, as well as to identify novel compounds and to detoxify them by diverse approaches (including enzyme antidotes). Special attention is given to the problems and possibilities of the toxicity control of the obtained recombinant proteins. The recombinant prions are discussed in the frame of their possible detoxification by enzymes. The review discusses the feasibility of obtaining recombinant variants of toxins in the form of protein molecules modified with fluorescent proteins, affine sequences and genetic mutations, allowing us to investigate the mechanisms of toxins' bindings to their natural receptors.
Collapse
Affiliation(s)
- Elena Efremenko
- Correspondence: ; Tel.: +7-(495)-939-3170; Fax: +7-(495)-939-5417
| | | | | |
Collapse
|